Auch in Q3/20 weitere ATM Offerings
"Cash, cash equivalents and marketable securities as of September 30, 2020, were $280.7 million, compared to $215.8 million as of December 31, 2019. During the quarter ended September 30, 2020, $74.0 million in net proceeds were received from the sale of 2,552,333 shares of the Company’s common stock pursuant to its at-the-market (ATM) offering. The $15.0 million milestone payment from Incyte was received after September 30, 2020."
- 74 Mio. $ / 2,55 Mio. Aktien = ~29,02$ pro Aktie in Q3/20
Angesichts der aktuellen Kurse von 21$, kein schlechter Schachzug.
"The Prescription Drug User Fee Act (PDUFA) target action date is December 18, 2020. Based on the current accrual rate of overall survival (OS) events in the Phase 3 SOPHIA study, MacroGenics now anticipates accrual of the 385th OS event, which triggers the final OS analysis, in the second half of 2021."
http://ir.macrogenics.com/news-releases/...orate-progress-and-third-4
|